Updates are available Correction dated 2024-07-18
Click to view Correction: https://doi.org/10.1186/s12885-024-12639-2
-
Authors
Nankivell, Paul
Gaunt, Piers
Gaunt, Claire
Sissons, Julia
Liaskou, Evaggelia
Jefferson, Yolande
Fulton-Lieuw, Tessa
Mittal, Saloni
Mehanna, Hisham
,
Abou-Foul, Ahmad
Karwath, Andreas
Lorenc, Ava
Main, Barry
Greaves, Colin
Moore, David
Secher, Denis
Watson, Eila
Gkoutos, Georgios
Ozakinci, Gozde
Wolstenholme, Jane
Dretzke, Janine
Brett, Jo
Duda, Joan
Matheson, Lauren
Jepson, Marcus
Wells, Mary
Calvert, Melanie
Rhodes, Pat
Kiely, Philip
Thomas, Steve
Winter, Stuart
Wong, Wai-lup
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (NIHR200861, NIHR200861, NIHR200861)
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 3 June 2024
First Online: 10 July 2024
Change Date: 18 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12885-024-12639-2
Declarations
:
: The trial is being performed in accordance with the recommendations guiding physicians in biomedical research involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki, Finland and stated in the respective participating countries laws governing human research, and Good Clinical Practice. The protocol was initially approved by the Yorkshire & The Humber - South Yorkshire Research Ethics Committee on 14-Sep-2021 (Ref. 21/YH/0175). The current protocol is v5.0 dated 19-Dec-2023. Protocol modifications will be notified to competent authority, ethics committee, and investigators by the PETNECK2 Trial Office.
: All patients provide written informed consent to participate.
: Not applicable.
: The authors declare no competing interests.
